Form 4 for RCKT ROCKET PHARMACEUTICALS, INC.
Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-17 · accession 0001140361-23-008102 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-02-22 | 2023-02-17 | RCKT | Shah Gaurav | CEO, Dir | S - Sale | $19.06 | -12.2K | 536.9K | -2% | -$232.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-17 | S | D | 12,194 | $19.06 | 536,885 | D | — | — | (F2) This transaction was executed in multiple brokered trades at prices ranging from $18.735 to $19.195. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |